REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CACancer J Clin. 2020;70(1):7-30.

2. Wu Y-L, Tsuboi M, He J, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer.

3. Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553:446-454.

4. Hanna NH, Robinson AG, Temin S, et al. Therapy for stage IV non-small cell lung cancer with driver alterations: ASCO and OH (CCC) joint guideline update. J Clin Oncol. 2021;39(9):1040- 1091.

5. Waks AG, Winer EP. Breast cancer treatment: a review. J Am Med Assoc. 2019;321(3):288.

6. Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. NEngl J Med. 2018;379:111-121.

7. Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. NEngl JMed. 2018;379(22):2108-2121.

8. Chow LQM. Head and neck cancer. NEngl JMed. 2020;382(1):60-72.

9. Johnson DE, Burtness B, Leemans CR, et al. Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020;6(1):92.

10. Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. NEngl JMed. 2021;384(13):1191-1203.

11. Shah MA, Kennedy EB, Catenacci DV et al. Treatment of locally advanced esophageal carcinoma: ASCO guideline. J Clin Oncol. 2020;38(23):2677-2694.

12. Smyth EC, Nilsson M, Grabsch HI, et al. Gastric cancer. Lancet. 2020;396(10251):635-648.

13. US Preventive Services Task Force, Davidson KW, Barry MJ, et al. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. J Am Med Assoc.

2021;325(19):1965-1977.

14. Shaukat A, Kahi CJ, Burke CA, et al. ACG clinical guidelines: colorectal cancer screening 2021. Am J Gastroenterol.

15. Dekker E, Tanis PJ, Vleugels JLA, et al. Colorectal cancer. Lancet. 2019;394(10207):1467-1480.

16. Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. J Am Med Assoc. 2021;325(7):669-685.

17. Mizrahi JD, Surana R, Valle JW, et al. Pancreatic cancer. Lancet. 2020;395(10242):2008-2020.

18. Villanueva A. Hepatocellular carcinoma. NEngl JMed. 2019;380(15):1450-1462.

19. Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6.

20. Roberto M, Botticelli A, Panebianco M, et al. Metastatic renal cell carcinoma management: from molecular mechanism to clinical practice. Front Oncol. 2021;11:657639.

21. Lenis AT, Lec PM, Chamie K. Bladder cancer: a review. J Am Med Assoc. 2020;324(19):1980.

22. US Preventive Services Task Force, Grossman DC, Curry SJ, et al. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. J Am Med Assoc. 2018;319(18):1901.

23. Rebello RJ, Oing C, Knudsen KE, et al. Prostate cancer. Nat Rev Dis Primers. 2021;7(1):9.

24. Hanna NH, Einhorn LH. Testicular cancer—discoveries and updates. NEngl J Med. 2014;371(21):2005-2016.

25. US Preventive Services Task Force, Curry SJ, Krist AH, et al. Screening for cervical cancer: US preventive Services Task Force recommendation statement. J Am Med Assoc. 2018;320(7):674.

26. Cohen PA, Jhingran A, Oaknin A, et al. Cervical cancer. Lancet. 2019;393(10167):169-182.

27. Lu KH, Broaddus RR. Endometrial cancer. NEngl JMed. 2020;383(21):2053-2064.

28. Matulonis UA, Sood AK, Fallowfield L, et al. Ovarian cancer. Nat Rev Dis Primers. 2016;2(1):16061.

29. Curti BD, Faries MB. Recent advances in the treatment of melanoma. N Engl J Med. 2021;384(23):2229-2240.

30. Wen PY, Weller M, Lee EQ, et al. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.

31. Gamboa AC, Gronchi A, Cardona K. Softtissue sarcoma in adults: an update on the current state of histiotypespecific management in an era of personalized medicine. CA Cancer J Clin. 2020;70(3):200-229.

32. Cazzola M. Myelodysplastic syndromes. NEngl JMed. 2020;383(14):1358-1374.

33. Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424-447.

34. Kantarjian H, Kadia T, DiNardo C, et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021;11(2):41.

35. Malard F, Mohty M. Acute lymphoblastic leukaemia. Lancet. 2020;395(10230):1146-1162.

36. Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966-984.

37. Burger JA. Treatment of chronic lymphocytic leukemia. NEngl J Med. 2020;383(5):460-473.

38. Connors JM, Cozen W, Steidl C, et al. Hodgkin lymphoma. Nat Rev Dis Primers. 2020;6(1):61.

39. Armitage JO, Gascoyne RD, Lunning MA, et al. Non-Hodgkin lymphoma. Lancet. 2017;390(10091):298-310.

40. Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, riskstratification and management. Am JHematol. 2020;95(5):548-567.

41. Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625-638